Friday, February 12, 2016

Archive: December, 2012

POSTED: Monday, December 31, 2012, 7:35 AM

At least on a headquarters basis, some of Johnson & Johnson's famous over-the-products could be moving from the Philadelphia suburb of Fort Washington to Chattanooga, Tenn.

Sanofi-aventis, the Paris-based pharmaceutical company with U.S. headquarters in New Jersey and a research facility in the Philadelphia suburb of Malvern, increased its over-the-counter consumer products business in 2009, when it spent $1.9 billion for Chattem, Inc.

Chattem, which has been in operation since the 1880s, is headquartered in Chattanooga, Tenn., and has name brands such as Gold Bond, Icy Hot, ACT, Cortizone-10, Selsun Blue and Unisom.

POSTED: Friday, December 28, 2012, 8:14 AM

Two former prosecutors say the ultimate impact of the decision in U.S. v. Caronia won't be known until further court action, but in the meantime, former colleagues prosecuting cases might be more careful in forthcoming cases.

But the Dec. 3 opinion also doesn't give a free pass to pharmaceutical companies and their sales reps to say anything about any drug.

"I don't think this opinion is a license to do that," said Geoff Kaiser, who was one of the U.S. Attorney's in Brooklyn who brought the original charges against Orphan Medical, Alfred Caronia and doctor Peter Gleason for off-label marketing. "I don't think it establishes that it's okay for a pharmaceutical company to promote an unapproved indication."

POSTED: Thursday, December 27, 2012, 7:59 AM

In something of a suggestion for a New Year's resolution, the U.S. Department of Health and Human Services recommended again Wednesday that people who have not gotten flu shots find a spot to get one.

If the needle is the issue, some vaccine is available via nasal spray.

The Food and Drug Administration notes that everyone six months of age and older should be vaccinated and that "seasonal flu vaccines have a very good safety track record."

POSTED: Thursday, December 27, 2012, 4:19 PM
This global powerhouse is based in New Brunswick, N.J. It was founded in 1887 and today boasts a multi-faceted business with more than 117,900 employees, 200 subsidiaries and a market cap of $198 billion. Products include Tylenol, Zyrtec, Benadryl; Band-Aid; Acuevue contact lenses. And much more. J&J expanded into pharmaceuticals in the 1970s and 1980s through acquisition. Recently, it has had to contend with product recalls at its McNeil unit; bone cement from Synthes, which it acquired in June; and settlements and lawsuits involving the marketing of anti-psychotic drug Risperdal.


Drugmakers Johnson & Johnson and Sanofi have a pending deal involving an element of J&J’s consumer products subsidiary, McNeil PPC Inc., according to a posting on the Federal Trade Commission web site.

But the deal will not include selling the McNeil Consumer Healthcare facility in Fort Washington, Montgomery County, according to McNeil spokeswoman Barbara Montresor.

McNeil PPC has several units, including McNeil Consumer Healthcare, and products such as Band Aids, Tylenol and Listerine.

POSTED: Monday, December 24, 2012, 9:27 AM

The never-ending - and often profit-driven - hope for miraculous cures and the reality of the health-care business was displayed again over the last few days.

The New York Times provided the latest story about three big pharmaceutical companies trying to figure out how to get the right molecules to overcome the wrong molecules and thereby  cure forms of cancer.

The link to the story is here.

POSTED: Friday, December 21, 2012, 9:18 AM

A team from Bloomberg News crunched data and reported that one in five U.S. insider-trading cases involve health-care stocks.

A corresponding Bloomberg survey of 30 health-care companies showed that those companies say their policies designed to prevent abuse are sufficient - or they refuse to publicly discuss the issue at all.

A link to the story is here.

POSTED: Thursday, December 20, 2012, 6:43 AM

Perhaps only in the strange business of pharmaceuticals would a company sue to have a federal agency declare that one of its products was in any way unsafe and then be disappointed when it loses the the suit.

But that's what happened with Endo Pharmaceuticals, Inc., a subsidiary of Endo Health Solutions, Inc., of Chadds Ford.

The drug in question is Opana ER, which is an opioid painkiller. That group of medicine has been a source of debate because of overdoses by abusers.

POSTED: Wednesday, December 19, 2012, 8:08 AM

Sir Peter Westmacott, the British ambassador to the United States, was in Philadelphia last week and spoke with reporters and editors from the Inquirer business section. Later that day, Westmacott was the featured guest at the British American Business Council of Greater Philadelphia holiday lunch at the Ritz Carleton Hotel.

A foreign service veteran, Westmacott was posted to Washington in the mid-1990s as the embassy's counselor for political and public affairs. He was ambassador to Turkey and then France before starting as U.S. ambassador in January of 2012.

Like other aspects of the US-UK friendship, the health-care systems are sometimes compared.

About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter